Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $24.25 Average Price Target from Analysts

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has earned a consensus rating of “Moderate Buy” from the eleven ratings firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $24.25.

A number of brokerages have commented on ARCT. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcturus Therapeutics in a research report on Friday, July 17th. Wall Street Zen upgraded shares of Arcturus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, July 18th.

Arcturus Therapeutics Trading Up 0.7%

ARCT opened at $5.79 on Thursday. The stock has a market capitalization of $164.55 million, a P/E ratio of -2.06 and a beta of 2.37. The stock has a 50-day moving average price of $6.93 and a 200-day moving average price of $7.44. Arcturus Therapeutics has a 12-month low of $5.50 and a 12-month high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Friday, May 8th. The biotechnology company reported ($0.95) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.08. The company had revenue of $2.06 million for the quarter, compared to analysts’ expectations of $6.30 million. Arcturus Therapeutics had a negative return on equity of 36.55% and a negative net margin of 143.80%. On average, equities research analysts predict that Arcturus Therapeutics will post -3.99 EPS for the current year.

Institutional Trading of Arcturus Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Osaic Holdings Inc. boosted its position in Arcturus Therapeutics by 51.8% during the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 738 shares during the period. CANADA LIFE ASSURANCE Co grew its stake in shares of Arcturus Therapeutics by 27.5% during the third quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 1,567 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Arcturus Therapeutics by 0.7% in the second quarter. Bank of America Corp DE now owns 292,429 shares of the biotechnology company’s stock worth $3,805,000 after buying an additional 2,098 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Arcturus Therapeutics by 163.4% in the second quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock worth $54,000 after buying an additional 2,586 shares during the period. Finally, Two Sigma Investments LP lifted its stake in shares of Arcturus Therapeutics by 3.3% in the 3rd quarter. Two Sigma Investments LP now owns 89,219 shares of the biotechnology company’s stock valued at $1,644,000 after acquiring an additional 2,857 shares during the last quarter. 94.54% of the stock is owned by institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.